GSK215083: a PET radioligand for 5-HT6 receptor; structure in first source
ID Source | ID |
---|---|
PubMed CID | 10172764 |
CHEMBL ID | 3260313 |
SCHEMBL ID | 3132360 |
MeSH ID | M0572302 |
Synonym |
---|
CHEMBL3260313 , |
SCHEMBL3132360 |
bdbm50011175 |
AKOS040748463 |
gsk215083 |
CS-0068639 |
HY-118836 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.0004 | 0.0000 | 0.3855 | 10.0000 | AID1137931 |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 0.0003 | 0.0002 | 0.5229 | 10.0000 | AID1137930 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1137930 | Displacement of [3H]-LSD from human 5-HT6 receptor expressed in HEK293 cells | 2014 | ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4 | Quinoline Derivatives as 5-HT6 Receptor PET Ligands. |
AID1137931 | Displacement of [125I]-R-O-DOI from human 5-HT2A receptor expressed in CHO-K1 cells by by liquid scintillation spectrometry | 2014 | ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4 | Quinoline Derivatives as 5-HT6 Receptor PET Ligands. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (33.33%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (66.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |